Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
AbbVie Inc. et al v. Amgen Inc. et al
Case Number:
1:16-cv-00666
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
September 28, 2017
AbbVie, Amgen End Patent Fight Over Humira Biosimilar
AbbVie Inc. and Amgen Inc. on Thursday announced a patent litigation settlement that will keep a biosimilar version of Humira, the world's best-selling drug, out of European pharmacies until 2018 and U.S. pharmacies until 2023.
-
August 05, 2016
Amgen's Humira Biosimilar Infringes 61 Patents, AbbVie Says
AbbVie Inc. on Thursday told a Delaware federal court that Amgen Inc. has infringed 61 of its patents by attempting to get approval for a biosimilar of AbbVie's blockbuster immunosuppressant Humira and urged the court to block the copycat drug.